Meantime, the expression level of PTPRC was positively related to drug sensitivity (EPI, CTX, DTX, PTX, TAM) (TCGA data, Figure 10A; local cohort, Figure 11A), and it was also a protective factor in the clinical treatment of breast cancer patients with neoadjuvant therapy or anti-endocrine therapy (Figure 10F). This evidence concerns the gene PTPRC and breast carcinoma.